A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.

2.50
Hdl Handle:
http://hdl.handle.net/10541/78775
Title:
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.
Authors:
Kell, W Jonathan; Burnett, Alan K; Chopra, Rajesh; Yin, John A; Clark, Richard E; Rohatiner, Ama; Culligan, Dominic; Hunter, Ann; Prentice, Archibald G; Milligan, Donald W
Abstract:
The feasibility of combining gemtuzumab ozogamicin (GO) with intensive chemotherapy as first-line treatment of acute myeloid leukemia (AML) was assessed in 72 patients, aged 17 to 59 years, as a prelude to the United Kingdom Medical Research Council (MRC) AML15 trial. Sixty-four patients received induction chemotherapy (DAT [daunorubicin, ara-C, thioguanine], DA [daunorubicin, ara-C], or FLAG-Ida [fludarabine, ara-C, G-CSF, idarubicin]) with GO on day 1. It was possible to give GO 3 mg/m2 with course 1, but 6 mg/m2 with course 1 or GO in a dose of 3 mg/m2 with consecutive courses was not feasible because of hepatotoxicity and delayed hematopoietic recovery. Thirty-one patients who were treated in consolidation with MACE (amsacrine, ara-C, etoposide) or HidAC (HidAC) and GO (3 mg/m2), and 23 in induction and consolidation, tolerated GO (3 mg/m2) well. Grade 4 liver toxicity and sinusoidal obstructive syndrome was more common in thioguanine-containing schedules (P =.007). Remission with course 1 was seen in 86% of patients. DA or FLAG-Ida with GO in induction achieved complete remission in 91% of patients and 78% of these patients are in continuous complete remission at 8 months. GO given with induction (DA or FLAG-Ida) and consolidation (MACE or HidAC) was well tolerated. These schedules are now being compared in the MRC AML15 trial in patients younger than 60 years.
Affiliation:
Department of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, Wales.
Citation:
A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. 2003, 102 (13):4277-83 Blood
Journal:
Blood
Issue Date:
15-Dec-2003
URI:
http://hdl.handle.net/10541/78775
DOI:
10.1182/blood-2003-05-1620
PubMed ID:
12933575
Type:
Article
Language:
en
ISSN:
0006-4971
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorKell, W Jonathan-
dc.contributor.authorBurnett, Alan K-
dc.contributor.authorChopra, Rajesh-
dc.contributor.authorYin, John A-
dc.contributor.authorClark, Richard E-
dc.contributor.authorRohatiner, Ama-
dc.contributor.authorCulligan, Dominic-
dc.contributor.authorHunter, Ann-
dc.contributor.authorPrentice, Archibald G-
dc.contributor.authorMilligan, Donald W-
dc.date.accessioned2009-08-26T16:13:54Z-
dc.date.available2009-08-26T16:13:54Z-
dc.date.issued2003-12-15-
dc.identifier.citationA feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. 2003, 102 (13):4277-83 Blooden
dc.identifier.issn0006-4971-
dc.identifier.pmid12933575-
dc.identifier.doi10.1182/blood-2003-05-1620-
dc.identifier.urihttp://hdl.handle.net/10541/78775-
dc.description.abstractThe feasibility of combining gemtuzumab ozogamicin (GO) with intensive chemotherapy as first-line treatment of acute myeloid leukemia (AML) was assessed in 72 patients, aged 17 to 59 years, as a prelude to the United Kingdom Medical Research Council (MRC) AML15 trial. Sixty-four patients received induction chemotherapy (DAT [daunorubicin, ara-C, thioguanine], DA [daunorubicin, ara-C], or FLAG-Ida [fludarabine, ara-C, G-CSF, idarubicin]) with GO on day 1. It was possible to give GO 3 mg/m2 with course 1, but 6 mg/m2 with course 1 or GO in a dose of 3 mg/m2 with consecutive courses was not feasible because of hepatotoxicity and delayed hematopoietic recovery. Thirty-one patients who were treated in consolidation with MACE (amsacrine, ara-C, etoposide) or HidAC (HidAC) and GO (3 mg/m2), and 23 in induction and consolidation, tolerated GO (3 mg/m2) well. Grade 4 liver toxicity and sinusoidal obstructive syndrome was more common in thioguanine-containing schedules (P =.007). Remission with course 1 was seen in 86% of patients. DA or FLAG-Ida with GO in induction achieved complete remission in 91% of patients and 78% of these patients are in continuous complete remission at 8 months. GO given with induction (DA or FLAG-Ida) and consolidation (MACE or HidAC) was well tolerated. These schedules are now being compared in the MRC AML15 trial in patients younger than 60 years.en
dc.language.isoenen
dc.subjectMyeloid Leukaemiaen
dc.subject.meshAcute Disease-
dc.subject.meshAdolescent-
dc.subject.meshAdult-
dc.subject.meshAge Factors-
dc.subject.meshAminoglycosides-
dc.subject.meshAmsacrine-
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCohort Studies-
dc.subject.meshCytarabine-
dc.subject.meshDoxorubicin-
dc.subject.meshEtoposide-
dc.subject.meshFeasibility Studies-
dc.subject.meshGranulocyte Colony-Stimulating Factor-
dc.subject.meshHepatitis, Toxic-
dc.subject.meshHumans-
dc.subject.meshIdarubicin-
dc.subject.meshLeukemia, Myeloid-
dc.subject.meshMiddle Aged-
dc.subject.meshPilot Projects-
dc.subject.meshRemission Induction-
dc.subject.meshThioguanine-
dc.subject.meshVidarabine-
dc.titleA feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia.en
dc.typeArticleen
dc.contributor.departmentDepartment of Haematology, University of Wales College of Medicine, Heath Park, Cardiff, CF14 4XN, Wales.en
dc.identifier.journalBlooden

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.